Nuvalent Inc

NUVLStocksPharmaceuticals MajorUnited StatesNasdaqUSD

Price

$124.01

Today

+0.0%

YTD

+23.5%

About

Nuvalent Inc - Class A is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. The company’s lead product candidates include an ROS1 inhibitor and an ALK inhibitor. Nuvalent is also developing a pipeline of other novel drug candidates targeting clinically proven kinase targets. Nuvalent can be found within the healthcare sector, and it is committed to developing innovative therapies that can help patients with cancer achieve better outcomes. The company has a strong team of experienced scientists and drug developers. Stay up to date on the share price of NUVL by adding it to your eToro watchlist.

Price chart

Closing price history for NUVL (1D candles).

Open positions

Current open positions for this instrument from your live portfolio.

Open positions

Unrealized return

+0.0%

No open positions exist for this instrument at the moment.

Financial insights

Valuation

P/E (TTM)-20.45

P/S (TTM)0.00

P/B (TTM)8.32

Market cap$9.79B

Cap tierMid-cap

Industry avg P/E-43.36

Profitability

Gross marginUnknown

EBIT margin0.00%

Net marginUnknown

ROE-41.19%

ROA-36.94%

Earnings & Revenue

Revenue (TTM)$0.00

Revenue growth (1Y)Unknown

EPS (TTM)-$6.06

Free cash flow$-312.79M

Total debt$0.00

Dividends & Risk

Dividend rate$0.00

Dividend yield0.00%

Beta (5Y)1.11

Employees228

Next earnings6 Aug '26

Trade history

Closed trades

Realized return

+0.0%

No stored closed trades exist for this instrument yet.